Spalding Surgical Center Going Paperless With MMRPro

LOS ANGELES, CA--(Marketwire - Feb 15, 2012) - MMRGlobal, Inc. (OTCBB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs) and electronic document management and imaging systems for healthcare professionals, today announced that Spalding Surgical Center of Beverly Hills, a leading Southern California outpatient general surgery center, is achieving its goal of becoming paperless using MMRPro. The Company's document management and imaging system is designed for hospitals, doctors' offices and other healthcare facilities to reduce costs, improve efficiency and make it easier for physicians and patients to track results and wellness progress electronically.

"MMRPro is proving that the rising costs of healthcare can be mitigated through the use of health IT without changing the ways that doctors do business," said Robert H. Lorsch, Chairman and CEO of MMRGlobal. "With digitization here and the days of pen and paper numbered, MMRPro gives doctors the ability to convert to computerized records without significantly changing the look and feel of the way the practice runs."

John R. Seitz, Co-founder, Chairman & CEO of Ambulatory Surgical Group, said, "Using MMRPro has significantly improved the workings of Spalding's office and staff. We are able to process information much faster than before, and we are using the system to scan an average of 1,200 pages daily, which effortlessly stores patient records online, saving time and money."

Spalding Surgical Center of Beverly Hills has also chosen MMRPro to manage their standard form database, increasing employee productivity and allowing the staff to shift their focus to patient care and not endless copying and printing. "MMRPro has given Spalding Surgical Center of Beverly Hills the confidence to convert to a completely paperless office very shortly," Seitz continued.

MMR will be at the HIMSS Conference and Exhibition in Las Vegas next week, February 20-24, to showcase its suite of health IT products including demonstrating how the MMRPro system can transition doctors, hospitals and other healthcare professionals to a paperless office as it is doing with Spalding Surgical Center of Beverly Hills with or without a full-featured EMR. HIMSS will also be MMR's Phase 2 launch of its MMR Stimulus Program, which enables hospitals using selected EMR systems to integrate the MMRPatientView patient portal as a standalone module and still participate in the MMR Stimulus Program, which can generate hundreds of thousands of dollars each year as patients upgrade to a full-featured MyMedicalRecords PHR.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId®/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature, whether or not such statement relates directly to the Company's future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company's products are not adopted or viewed favorably by the healthcare community; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; programs and initiatives including the MMR Stimulus Program; ability to establish and maintain strategic relationships; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; maintaining, developing and defending our intellectual property rights; marketing and exploitation of our patent portfolio; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.